CA-SYSDIG,-INC.
28.4.2021 13:02:11 CEST | Business Wire | Press release
Sysdig, Inc., the secure DevOps leader, today announced a $188 million Series F funding round at a valuation of $1.19 billion. This round brings Sysdig ’s total funding to $394 million since inception. The financing was led by Premji Invest & Associates and Third Point Ventures, with participation from Accel, Bain Capital Ventures, DFJ Growth, Glynn Capital, Goldman Sachs, Insight Partners, and Next47. The company also announced that Robert Schwartz from Third Point Ventures, Sandesh Patnam from Premji Invest & Associates, and Enrique Salem from Bain Capital Ventures have joined its board of directors .
Blog from CEO Suresh Vasudevan: Our $188M funding round fuels our mission to help customers confidently run modern cloud applications
The Sysdig Secure DevOps Platform uniquely addresses the challenges of securing containers, Kubernetes, and public cloud infrastructure. Sysdig is trusted by hundreds of leading enterprises, including Worldpay by FIS, Yahoo Japan, IBM, and JW Player to confidently run modern cloud applications while managing security risks and meeting compliance requirements.
This round follows strong growth in 2020, a rapidly expanding customer base, a thriving open source community, and a massive growth opportunity with containers and cloud.
Key Milestones:
- New annual contract value (ACV) added during the second half of the 2021 fiscal year (FY21) was 2.3 times the amount added in the same period, the previous fiscal year,* reflecting increasing cloud adoption and momentum throughout 2020.
- 450 enterprise customers, including dozens of large global enterprises, with an average annual recurring revenue (ARR) of more than $500,000 across the top 50 purchasing customers.
- Strong pattern of expansion by customers as demonstrated by an annual net revenue retention (NRR) of 140% at the end of FY21.
- With nearly 24 million downloads, including 1.7 million in the last month, Falco adoption has increased 300% in the last year.
- Sysdig significantly expanded the total addressable market (TAM) beyond container and Kubernetes security to include cloud security with the addition of continuous cloud security posture management (CSPM) in 2021. The served addressable market (SAM) also increased with the delivery of more than 50 significant features last year, including the first inline scanning for Fargate , zero trust network security , and cloud-scale Prometheus monitoring .
*The 2021 fiscal year ran from February 2020 - January 2021.
In November 2020, Gartner increased its 2021 public cloud forecast to total $304.9 billion, up from $257.5 billion in 2020. [1] Modern applications are increasingly built as highly distributed microservices, leveraging containers and Kubernetes, and a vast array of services on public cloud platforms. While this shift accelerates innovation, it presents unique challenges that legacy security tools, built with a proprietary, firewall mindset, are unable to address. To manage risk without slowing down application delivery, companies need a security stack:
- Architected for secure DevOps.
- Built on open source to accelerate innovation and drive standardization.
- Delivered as SaaS for simplicity and scale.
- That provides deep visibility across containers and cloud.
Run Containers, Kubernetes, and Cloud Applications Confidently with Secure DevOps
The Sysdig Secure DevOps Platform provides security and visibility to confidently run containers, Kubernetes, and cloud. Customers rely on the platform to secure the software build pipeline, detect and respond to runtime threats, monitor service health, and continuously validate cloud security posture and compliance.
Sysdig’s SaaS deployment model and curated, out-of-the-box workflows enable companies to reduce security risk while also improving operational efficiency by 25-50 percent. With functionality that spans cloud security posture, cloud workload protection platform, and container monitoring markets, 85 percent of new customers purchase the platform solution, replacing three point solutions.
Sysdig was founded as an open source company and the Sysdig Secure DevOps Platform was built on an open source foundation to address the security challenges of modern cloud applications. Open source sysdig and Falco are projects that were created by Sysdig to leverage deep visibility as a foundation for security, and they have become standards for container and cloud threat detection and incident response. Falco, which was contributed to the Cloud Native Computing Foundation (CNCF) in 2018, is now an incubating-hosted level project. Last year, Sysdig announced full compatibility and scalability for Prometheus, the CNCF project second in popularity to Kubernetes. Sysdig’s CSPM capability incorporates the popular Cloud Custodian, a CNCF project for static configuration checks.
Focus of this Investment
This new round of investment will enable Sysdig to invest in continued innovation in its open source foundation as well as in its secure DevOps platform, and grow research and development teams in Raleigh, Spain, Italy, Belgrade, and San Francisco. The funding will drive expansion of sales and marketing in existing markets within the United States, Europe, Japan, and Australia, as well as entry into newer markets in the Asia-Pacific region. A key emphasis will be on continuing to build ecosystem and channel partnerships and local SaaS regions around the globe.
Quotes
Enrique Salem, Partner, Bain Capital Ventures: “The current security stack based on a firewall mentality and promoted by incumbents is irrelevant in the cloud. Sysdig takes a secure DevOps approach, allowing teams to ship cloud apps faster while managing security risk. They built on an open source security stack, which we see accelerates innovation and adoption.”
Sandesh Patnam, US Managing Partner, Premji Invest & Associates: “The cloud is driving a transformative shift in the way applications are developed and secured. This levels the playing field for young, innovative companies to emerge as leaders in this new, exciting category. We are extremely deliberate in our investments and expect Sysdig will not only have a successful IPO, but deliver strong long-term returns in the public market.”
Robert Schwartz, Managing Partner, Third Point Ventures: “Sysdig took several steps early on that differentiated it from other solutions, including taking an open source approach to container and Kubernetes security well before others jumped on the bandwagon. This has paid off tremendously for them. Sysdig has a marquee customer base and proven its ability to scale. We’re excited to be joining the Sysdig team and can’t wait to help them accelerate from here.”
Ping Li, Partner, Accel: “Accel partnered with Sysdig early on, with a belief that a DevSecOps stack, based on open source, deployed as SaaS is a winning formula. Today, they are the clear leader in runtime security for containers and cloud.”
Suresh Vasudevan, Chief Executive Officer, Sysdig: “Sysdig was founded as an open source company and architected for secure DevOps. In contrast, Palo Alto was founded as a proprietary firewall company, and that mindset slows app delivery in the cloud. The leading security stack for cloud delivered apps will be built on open source with a secure DevOps approach that delivers deep visibility into containers and cloud.”
[1] Gartner, Gartner Forecasts Worldwide Public Cloud End-User Spending to Grow 18% in 2021, Katie Costello and Meghan Rimol, 17 November 2020
About Sysdig
Sysdig is driving the secure DevOps movement, empowering organizations to confidently secure containers, Kubernetes, and cloud. With Sysdig, teams secure the build, detect and respond to threats, continuously validate cloud posture and compliance, and monitor performance. Sysdig is a SaaS platform, built on an open source stack that includes Falco and sysdig OSS, the open standards for runtime threat detection and response. Hundreds of companies rely on Sysdig for container and cloud security and visibility. Learn more at www.sysdig.com .
View source version on businesswire.com: https://www.businesswire.com/news/home/20210428005369/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
International Human Rights Lawyer Jared Genser and Former White House Counsel Lanny J. Davis Join Legal and Advocacy Team Supporting Cambodian Businessman Yim Leak, Seiden Law LLP Announces18.9.2026 19:52:00 CEST | Press release
Jared Genser, one of the world's most recognized international human rights lawyers, and Lanny J. Davis, an adviser to former presidents George W. Bush and Bill Clinton, join the legal and advocacy team for Cambodian businessman Yim Leak and challenge what they call a coordinated smear campaign in Thailand. International human rights lawyer Jared Genser and Lanny J. Davis, who has close ties to two former US presidents and a worldwide reputation for defending those under attack with lies and smears, and for repairing the damage done to their reputations, have joined the legal and advocacy team supporting Cambodian businessman Yim Leak, Seiden Law LLP, which serves as Yim Leak's chief global counsel, announced today. Their first move is to hold the Thai government accountable, framing its conduct as either complicit in or willfully blind to a sustained smear campaign against Yim. Genser is Managing Director of Perseus Strategies, an international law firm. Over more than two decades, he
Ningbo FEED Meeting Confirms Full Confidence in Q1 2027 FID for Allied Biofuels’ US$6.1 Billion Presidential Decree-Backed SAF and e-SAF Project18.9.2026 17:38:00 CEST | Press release
Allied Biofuels has held a major Front-End Engineering Design (FEED) meeting at Sinopec’s office in Ningbo, China, bringing together Allied Biofuels, Sinopec Engineering Group Co., Ltd. of China, Topsoe A/S of Denmark, Sasol South Africa Limited, and Plug Power of the United States — the principal international engineering and technology providers supporting its US$6.1 billion Presidential Decree-backed Sustainable Aviation Fuel (SAF) and e-SAF project in Uzbekistan. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260918708077/en/ FEED Meeting - Ningbo, China At the joint FEED meeting of the project’s core engineering and technology stakeholders, the discussions established clear alignment on engineering responsibilities, technology interfaces, design deliverables, project integration and the coordinated execution programme required to advance the project through FEED. All stakeholders working on the project expressed full co
Corcept Announces CHMP Opinion Recommending EU Marketing Authorization for Lifyorli® (Relacorilant)18.9.2026 14:00:00 CEST | Press release
Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol, today announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has recommended that the European Commission (EC) should approve relacorilant, combined with the chemotherapy drug nab-paclitaxel, for the treatment of patients with platinum-resistant ovarian cancer. The CHMP’s recommendation is based on positive data from Corcept’s Phase 2 and pivotal Phase 3 ROSELLA trials, in which patients receiving relacorilant combined with nab-paclitaxel experienced improved progression-free and overall survival compared to patients who received nab-paclitaxel alone. The safety profile of relacorilant plus nab-paclitaxel in these trials was consistent with the safety profile of nab-paclitaxel monoth
Enhertu® Recommended for Approval in the EU by CHMP as Adjuvant Treatment for Patients with Residual Disease After Neoadjuvant Treatment for HER2 Positive Early Breast Cancer18.9.2026 14:00:00 CEST | Press release
Recommendation based on DESTINY-Breast05 phase 3 trial results that showed Enhertu reduced the risk of invasive disease recurrence or death by 53% versus T-DM1 Daiichi Sankyo and AstraZeneca’s Enhertu has the potential to become a new standard of care in this early breast cancer setting Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the adjuvant treatment of adult patients with resected HER2 positive breast cancer who have residual invasive disease after neoadjuvant taxane-based and HER2 targeted treatment. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from the DESTINY-Breast05 phase 3 trial presented at th
CHMP Recommends EU Approval of New Indication for Alfasigma’s Jyseleca® (filgotinib), Treatment of Adults With Axial Spondyloarthritis18.9.2026 12:58:00 CEST | Press release
The information contained within this press release is for the purpose of scientific exchange.It is intended for scientific, financial and investor media only.If approved, Jyselecawill be indicated for the treatment of patients with active axial spondyloarthritis (axSpA), both non-radiographic and radiographic forms of the disease, who have responded inadequately to conventional therapy.Despite the availability of multiple treatment options, nearly half of people living with axSpA do not respond adequately to current therapies, and just 10-20% reach inactive disease within 16-24 weeks of initiating treatment.CHMP’s positive opinion is based on findings from the OLINGUITO Phase 3 study, where improvements in the signs and symptoms of axSpA with filgotinib were observed early and maintained over 52 weeks of treatment.Jyselecais already approved in Europe and the United Kingdom, for the treatment of moderate to severe rheumatoid arthritis and ulcerative colitis. Alfasigma S.p.A, a global
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
